SEC Form 4 · accession 0001209191-17-025763
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly J Popovits
Officer — President and CEO · Director
Period of report
Apr 3, 2017
Accepted (ET)
Apr 5, 2017 · 5:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 3, 2017 | M | 2,900 | $23.31 | A | 81,136 | D | |
| Common StockF1 | Apr 3, 2017 | M | 2,100 | $17.33 | A | 83,236 | D | |
| Common StockF2,F3,F4,F1 | Apr 3, 2017 | S | 5,000 | $31.3013 | D | 78,236 | D | |
| Common Stock | Mar 20, 2017 | G | 876 | $0.00 | D | 199,975 | I | Held by the Popovits 2010 Trust |
| Common Stock | Mar 21, 2017 | G | 488 | $0.00 | D | 199,487 | I | Held by the Popovits 2010 Trust |
| Common Stock | holding | — | — | — | 12,298 | I | Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits | |
| Common Stock | holding | — | — | — | 16,825 | I | Held in trust for the benefit of Ms. Popovits' son, of which Ms. Popovits is trustee. | |
| Common Stock | holding | — | — | — | 199,487 | I | Held by the Popovits 2010 Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F5 | $23.31 | Apr 3, 2017 | M | 2,900 | D | — | Dec 6, 2017 | Common Stock | 0 | 0 | D |
| Employee Stock Option (right to buy)F6 | $17.33 | Apr 3, 2017 | M | 2,100 | D | — | Dec 4, 2018 | Common Stock | 0 | 57,900 | D |
Explanation of responses
- F1Includes an aggregate of 45,294 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 6, 2016.
- F3Represents weighted average sale price. Actual sale prices ranged from $31.05 to $31.60.
- F4Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F5The option became exercisable as to 25% of the shares on December 6, 2008, and became exercisable as to 1/48th of the shares each full month thereafter.
- F6The option became exercisable as to 25% of the shares on December 4, 2009, and became exercisable as to 1/48th of the shares each full month thereafter.